Daiichi Sankyo Co Ltd
4568: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥5,593.00 | Mfjvkr | Hnycnyqp |
Daiichi Sankyo’s ADC Platform Has Created Its First Winner With Enhertu
Business Strategy and Outlook
Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long history, it also has numerous lucrative business lines including generics, anticoagulants, painkillers, and heart medications. In 2019 it formed a partnership with AstraZeneca to codevelop and cocommercialize Enhertu and Dato-DXd, its two leading assets from its ADC platform. We expect its ADC platform and other pipeline assets to drive growth over the next 10 years.